These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1169 related items for PubMed ID: 26373734

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.
    Matsuda Y, Yamauchi T, Hosono N, Uzui K, Negoro E, Morinaga K, Nishi R, Yoshida A, Kimura S, Maekawa T, Ueda T.
    Cancer Sci; 2016 Jul; 107(7):1029-38. PubMed ID: 27166836
    [Abstract] [Full Text] [Related]

  • 4. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
    Cassuto O, Dufies M, Jacquel A, Robert G, Ginet C, Dubois A, Hamouda A, Puissant A, Luciano F, Karsenti JM, Legros L, Cassuto JP, Lenain P, Auberger P.
    Oncotarget; 2012 Dec; 3(12):1557-65. PubMed ID: 23238683
    [Abstract] [Full Text] [Related]

  • 5. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y, Ozkan T, Altinok Gunes B, Bozkurt S, Karadag A, Karabay AZ, Sunguroglu A.
    Cell Mol Biol (Noisy-le-grand); 2018 May 15; 64(6):23-30. PubMed ID: 29808796
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia.
    Kayabasi C, Okcanoglu TB, Yelken BO, Asik A, Susluer SY, Avci CB, Saydam G, Gunduz C.
    Gene; 2017 Dec 30; 637():173-180. PubMed ID: 28942039
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
    Kim DS, Na YJ, Kang MH, Yoon SY, Choi CW.
    Korean J Intern Med; 2016 Mar 30; 31(2):357-66. PubMed ID: 26874514
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.
    Okabe S, Tauchi T, Tanaka Y, Ohyashiki K.
    Biochem Biophys Res Commun; 2013 Jun 07; 435(3):506-11. PubMed ID: 23684619
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X, Zhao H, Li Y, Fan J, Sun Y, Wang S, Wang Z, Song P, Ju D.
    Autophagy; 2015 Jun 07; 11(2):355-72. PubMed ID: 25701353
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation.
    Fang Z, Jung KH, Yan HH, Kim SJ, Son MK, Rumman M, Lee H, Kim KW, Yoo HD, Hong SS.
    Int J Oncol; 2015 Jul 07; 47(1):253-61. PubMed ID: 25963192
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.